117 related articles for article (PubMed ID: 22213442)
21. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
22. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
23. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.
Ettinger SL; Sobel R; Whitmore TG; Akbari M; Bradley DR; Gleave ME; Nelson CC
Cancer Res; 2004 Mar; 64(6):2212-21. PubMed ID: 15026365
[TBL] [Abstract][Full Text] [Related]
24. Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma.
Yuan S; Pan Q; Fu C; Bi Z
Mol Cell Biochem; 2011 Sep; 355(1-2):281-7. PubMed ID: 21573994
[TBL] [Abstract][Full Text] [Related]
25. Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.
Kanaoka R; Kushiyama A; Seno Y; Nakatsu Y; Matsunaga Y; Fukushima T; Tsuchiya Y; Sakoda H; Fujishiro M; Yamamotoya T; Kamata H; Matsubara A; Asano T
PLoS One; 2015; 10(6):e0127467. PubMed ID: 26039047
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial DNA determines androgen dependence in prostate cancer cell lines.
Higuchi M; Kudo T; Suzuki S; Evans TT; Sasaki R; Wada Y; Shirakawa T; Sawyer JR; Gotoh A
Oncogene; 2006 Mar; 25(10):1437-45. PubMed ID: 16278679
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
Lau KM; Chan QK; Pang JC; Ma FM; Li KK; Yeung WW; Cheng AS; Feng H; Chung NY; Li HM; Zhou L; Wang Y; Mao Y; Ng HK
Acta Neuropathol; 2012 Apr; 123(4):553-71. PubMed ID: 22249617
[TBL] [Abstract][Full Text] [Related]
28. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
[TBL] [Abstract][Full Text] [Related]
29. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
30. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
[TBL] [Abstract][Full Text] [Related]
31. Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling.
Yang Y; Ikezoe T; Zheng Z; Taguchi H; Koeffler HP; Zhu WG
Int J Oncol; 2007 Sep; 31(3):593-600. PubMed ID: 17671686
[TBL] [Abstract][Full Text] [Related]
32. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
33. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME
Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
36. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
37. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
Rocchi P; So A; Kojima S; Signaevsky M; Beraldi E; Fazli L; Hurtado-Coll A; Yamanaka K; Gleave M
Cancer Res; 2004 Sep; 64(18):6595-602. PubMed ID: 15374973
[TBL] [Abstract][Full Text] [Related]
38. Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
Miyazawa Y; Sekine Y; Kato H; Furuya Y; Koike H; Suzuki K
Prostate; 2017 Mar; 77(4):337-349. PubMed ID: 27862098
[TBL] [Abstract][Full Text] [Related]
39. Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells.
Peng L; Malloy PJ; Wang J; Feldman D
Endocrinology; 2006 Oct; 147(10):4599-607. PubMed ID: 16825320
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
